-
Cytoskeleton-Dependent Mechanotransduction Drives Autophagy
2026-09-29
The reference study provides direct evidence that microfilaments are required for autophagy induced by compressive mechanical stress, while microtubules make an auxiliary contribution. Its combination of cytoskeletal perturbation, fluorescent imaging, and western blotting offers a useful framework for studying how physical forces are converted into intracellular autophagy responses.
-
WEHI-539: A Practical BCL-XL Inhibitor Workflow
2026-09-29
WEHI-539 provides a selective way to test whether cell survival depends on BCL-XL rather than relying on nonspecific cytotoxicity. This workflow connects mitochondrial apoptosis measurements, BAX/BAK validation, and cancer stem cell sensitization while addressing the compound’s challenging insolubility.
-
Fucoidan as a State-Aware Cancer Research Tool
2026-09-28
Fucoidan is a Sulfated α-L-Fucan with apoptosis, immune, and metastasis-related activity. This article presents a state-aware assay framework that connects fucoidan biology with cancer-cell plasticity research without overstating evidence.
-
BH3 Mimetics Clear Senescent Breast Cancer Cells
2026-09-28
A 2020 study found that chemotherapy-induced senescent cells in TP53 wild-type breast cancer models can become vulnerable to BH3 mimetics, although sensitivity develops over time and varies with apoptotic dependencies. In a mouse model, giving ABT-263 after chemotherapy increased tumor regression and survival, supporting further study of senescent-cell targeting as a strategy against residual disease.
-
Mitomycin C Workflows for Cancer Research
2026-09-27
Use Mitomycin C to probe DNA damage responses and apoptosis, or to test whether cancer cells become more responsive to TRAIL. This guide connects practical dosing and solubility choices to a BAF53a glioma study while clearly separating established findings from experiments that still require validation.
-
EPI-001: An AR N-Terminal Domain Inhibitor
2026-09-26
EPI-001 lets researchers interrogate androgen receptor activity through its N-terminal domain, including signaling that may persist when the ligand-binding domain is absent. This workflow connects established prostate cancer models with a promising, still exploratory TNBC application, and pairs migration readouts with molecular checks to help separate pathway effects from general toxicity.
-
10074-G5 in Cell Viability and c-Myc Assays
2026-09-25
A practical guide to using 10074-G5 (SKU C5722) in c-Myc-focused viability, proliferation, and cytotoxicity experiments. It connects reported potency data with assay controls, solvent handling, interpretation limits, and a transparent approach to product selection.
-
Alfuzosin HCl in BPH Research: Practical Workflows
2026-09-25
Build reproducible studies of α1-adrenergic receptor signaling and lower urinary tract smooth muscle relaxation with a workflow tailored to Alfuzosin HCl. Practical assay guidance covers receptor and tissue models, solution handling, formulation testing, and how to interpret results without confusing symptom-relief research with antibacterial activity.
-
Cabazitaxel (XRP6258): Practical Research Workflow
2026-09-24
Cabazitaxel (XRP6258) is a taxoid compound for investigating microtubule dynamics disruption and antiproliferative responses, including in taxane-resistant cell models. It is water-insoluble, so use a validated DMSO- or ethanol-based preparation with matched vehicle controls; do not assume an aqueous stock or long-term solution stability.
-
4-Hydroxytamoxifen: Practical Workflow and QC
2026-09-24
4-Hydroxytamoxifen (4-OHT) is a DMSO-compatible estrogen receptor modulator for controlled cell-based and selected animal research workflows. It is not suitable for direct water- or ethanol-based preparation; define dose and vehicle controls in a pilot because the product information does not specify a universal working concentration or treatment schedule.
-
Cyclophosphamide: From Mechanism to Translation
2026-09-23
Cyclophosphamide can connect tumor-cell killing with immune modulation—but its hepatic activation and context-dependent effects demand careful model design. This guide translates its mechanism, protocol considerations, and a cross-domain lesson from neutropenic infection research into practical decisions for translational teams.
-
Danazol Research Workflows and Model Insights
2026-09-23
Danazol enables controlled investigation of androgen receptor signaling, steroidogenesis, and hypothalamic–pituitary–gonadal axis regulation. This practical guide connects cell-based assays with a recently reported rat model of precocious puberty and provides preparation, workflow, and troubleshooting strategies.
-
Niclosamide: From STAT3 Mechanism to Translation
2026-09-22
A mechanism-first guide to using Niclosamide in cancer research, integrating STAT3 biology, apoptosis and cell-cycle readouts, assay design, formulation control, and translational interpretation.
-
AZD2461: PARP Assays for Drug-Resistance Research
2026-09-22
AZD2461 helps researchers connect PARP-1 target engagement with cytotoxicity, G2-phase arrest, and resistance phenotypes in breast cancer models. This workflow emphasizes paired viability and cell-death measurements so investigators can distinguish growth inhibition from true killing and evaluate Pgp-related resistance more rigorously.
-
Drug Response Metrics in Cancer In Vitro
2026-09-21
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell killing are related but non-equivalent components of anticancer drug response. The framework provides a practical basis for combining time-resolved viability measurements with direct death and apoptosis assays in cancer research.